In that subtype of AML, treatment with all-trans-retinoic acid (ATRA) and ATO results in degradation of the PML-RARα fusion oncogene, differentiation of tumor cells, and apoptosis in leukemic blasts. This evidence concerns the gene RARA and neoplasm.